{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-077217","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2022-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.704030+00:00","generated_at":"2026-06-26T22:20:26.167396+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Apellis reports positive 18-month Phase 3 data for pegcetacoplan in GA; NDA planned Q2 2022","bullets":["OAKS GA: monthly pegcetacoplan reduced lesion growth 22% (p<0.0001); every-other-month 16% (p=0.0018) at month 18.","DERBY GA: monthly reduction 13% (p=0.0254); every-other-month 12% (p=0.0332); effects improved vs months 0-6.","Combined: monthly reduction improved from 13% (months 0-6) to 21% (months 12-18); every-other-month from 12% to 17%.","Safety: endophthalmitis rate 0.044% per injection; intraocular inflammation 0.23%; no retinal vasculitis or vein occlusion.","Company plans to submit NDA to FDA for intravitreal pegcetacoplan in GA in Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-077217","json":"https://secwatch.observer/filing/0001193125-22-077217.json","markdown":"https://secwatch.observer/filing/0001193125-22-077217.md","text":"https://secwatch.observer/filing/0001193125-22-077217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312522077217/0001193125-22-077217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312522077217/d223867d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:20:26.167396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}